Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023
January 30 2023 - 8:00AM
Roivant Sciences (Nasdaq: ROIV) today announced that it will host a
live conference call and webcast at 8:00 a.m. ET on Monday,
February 13, 2023, to report its financial results for the third
quarter ended December 31, 2022 and provide a corporate update.
To access the conference call by phone, please register online
using this registration link. The presentation and webcast details
will also be available under “Events & Presentations” in the
Investors section of the Roivant website at
https://investor.roivant.com/news-events/events. The archived
webcast will be available on Roivant’s website after the conference
call.
Roivant also announced its attendance and participation in the
following upcoming investor conferences:
- SVB Securities Global Biopharma
Conference on Tuesday, February 14 including a fireside chat at
12:00 p.m. ET
- Cowen 43rd Annual Health Care
Conference on Tuesday, March 7 including a fireside chat at 11:10
a.m. ET and a panel discussion at 12:50 p.m. ET
A live webcast of each presentation will be available under
“Events & Presentations” in the Investors section of the
Roivant website.
About Roivant Sciences
Roivant's mission is to improve the delivery of healthcare to
patients by treating every inefficiency as an opportunity. Roivant
develops transformative medicines faster by building technologies
and developing talent in creative ways, leveraging the Roivant
platform to launch Vants – nimble and focused biopharmaceutical and
health technology companies. For more information, please
visit www.roivant.com.
Roivant Sciences Forward-Looking
Statements
This press release contains forward-looking statements.
Statements in this press release may include statements that are
not historical facts and are considered forward-looking within the
meaning of Section 27A of the Securities Act of 1933, as amended
(the “Securities Act”), and Section 21E of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), which are usually
identified by the use of words such as “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intends,” “may,”
“might,” “plan,” “possible,” “potential,” “predict,” “project,”
“should,” “would” and variations of such words or similar
expressions. The words may identify forward-looking statements, but
the absence of these words does not mean that a statement is not
forward-looking. We intend these forward-looking statements to be
covered by the safe harbor provisions for forward-looking
statements contained in Section 27A of the Securities Act and
Section 21E of the Exchange Act.
Our forward-looking statements include, but are not limited to,
statements regarding our or our management team’s expectations,
hopes, beliefs, intentions or strategies regarding the future, and
statements that are not historical facts, including statements
about the clinical and therapeutic potential of our products and
product candidates, the availability and success of topline results
from our ongoing clinical trials and any commercial potential of
our products and product candidates. In addition, any statements
that refer to projections, forecasts or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking statements.
Although we believe that our plans, intentions, expectations and
strategies as reflected in or suggested by those forward-looking
statements are reasonable, we can give no assurance that the plans,
intentions, expectations or strategies will be attained or
achieved. Furthermore, actual results may differ materially from
those described in the forward-looking statements and will be
affected by a number of risks, uncertainties and assumptions,
including, but not limited to, those risks set forth in the Risk
Factors section of our filings with the U.S. Securities and
Exchange Commission. Moreover, we operate in a very competitive and
rapidly changing environment in which new risks emerge from time to
time. These forward-looking statements are based upon the current
expectations and beliefs of our management as of the date of this
press release, and are subject to certain risks and uncertainties
that could cause actual results to differ materially from those
described in the forward-looking statements. Except as required by
applicable law, we assume no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contacts
InvestorsRoivant Investor
Relationsir@roivant.com
MediaStephanie LeeRoivant
Sciencesstephanie.lee@roivant.com
Roivant Sciences (NASDAQ:ROIV)
Historical Stock Chart
From Jul 2024 to Aug 2024
Roivant Sciences (NASDAQ:ROIV)
Historical Stock Chart
From Aug 2023 to Aug 2024